Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team w...
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management ...
Lyell Immunopharma press release ( NASDAQ: LYEL ): Q3 net loss of $43.7M. For further details see: Lyell Immunopharma reports Q3 results
Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical development Cash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement ...
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a c...
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management ...
Lyell Immunopharma ( NASDAQ: LYEL ) on Thursday said the U.S. FDA had cleared its investigational new drug application to start a phase 1 trial for its experimental cancer therapy LYL845. LYEL stock +4.1% to $8.42 after hours. LYL485 is a tumor infiltrating lymphocyte ...
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved function Phase 1 trial to initially enroll patients with relapsed and/or refractory metastatic...
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinic...
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the exe...
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
Lyell Immunopharma Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 56.4% to $0.21 on volume of 112,154,340 shares Rivian Automotive Inc. (RIVN) rose 31.8% to $15.76 on volume of 70,797,368 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 48.3% to $...
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 10 6 CAR T cells) First demonstration that CAR T cells enhanced with anti-exhaus...